COVID-19 Clinical Trials
Photo: iStock
UCLA conducts research for a wide range
of medical disorders and offers patients
opportunities to participate in research and
clinical trials. Following is a description of just
one of our many active clinical trials dedicated
to the research and treatment of COVID-19,
followed by a list of some of the other clinical
studies at UCLA Health that are actively
recruiting participants.
COVID-19 Booster Vaccine in
Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive,
open-label clinical trial comparing the immune
response to different COVID-19 vaccine booster
doses in participants with autoimmune disease
requiring immunosuppressive medications.
All study participants will have negative
serologic or suboptimal responses (defined
as a Roche Elecsys® Anti-SARS-CoV-2 S(RBD) result = 50 U/mL) to initial COVID-19
vaccine regimen with Moderna COVID-19
vaccine, Pfizer-BioNTech COVID-19 vaccine
or Janssen COVID-19 vaccine. The study will
initially focus on five autoimmune diseases:
systemic lupus erythematosus (SLE),
rheumatoid arthritis (RA), multiple sclerosis
(MS), systemic sclerosis (SSc) and pemphigus.
More open and actively recruiting clinical studies
at UCLA Health:
- ACTIV-3: Therapeutics for Inpatients with COVID-19
- Chinese Herbal Formula for COVID-19
- Accelerating COVID-19 Therapeutic
Interventions and Vaccines 4 ACUTE
- Acupressure for COVID-19 Related
Quality of Life and Stress
- COVID Evaluation of Risk for Emergency
Departments (COVERED) Project
- COVID-19 Questionnaire in UCLA
Rheumatoid Arthritis Patients
- NCI COVID-19 in Cancer Patients,
NCCAPS Study
- Observational Cohort of Hospitalized Patients
with COVID-19 at UCLA
- Role of Children in Transmission of COVID-19
to Immunocompromised Patients
- ACTIV-5 / Big Effect Trial (BET-B) for the
Treatment of COVID-19
- COVID-19 Booster Vaccine in Autoimmune
Disease Non-Responders
- Compassionate Use of Leronlimab for Treatment
of COVID-19 (SARS-CoV-2 Infection)
- COVID-19 SARS Vaccinations: Systemic Allergic
Reactions to SARS-CoV-2 Vaccinations
- Innovative Support for Patients with SARSCoV-
2 Infections (COVID-19) Registry (INSPIRE)
- PK and Safety of Remdesivir for Treatment
of COVID-19 in Pregnant and Nonpregnant
Women in the U.S.
- The Safety of Molnupiravir (EIDD-2801) and
Its Effect on Viral Shedding of SARS-CoV-2
(END-COVID)
- An Observational Study Evaluating Viral Shedding
and Development of Immune Responses in
Mother-Infant Pairs Affected by COVID-19
- COVID-19 Critical Care Consortium
Incorporating the ExtraCorporeal Membrane
Oxygenation for 2019 novel Coronavirus Acute
Respiratory Disease (ECMOCARD)
- COVID-19 Surveillance in Healthcare Workers
and Patients: Observational Studies from the
Influenza Vaccine Effectiveness in the Critically
Ill (IVY) Network
- Study of Mavrilimumab (KPL-301) in
Participants Hospitalized with Severe
Coronavirus Disease 2019 (COVID-19)
Pneumonia and Hyper-inflammation
- Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Efficacy of
Remdesivir (GS-5734™) in Participants
from Birth to < 18 Years of Age With
Coronavirus Disease 2019 (COVID-19)
For more information, including
descriptions of active COVID-19 clinical
trials at UCLA Health >
